Goldman Sachs’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $145M | Buy |
639,803
+225,075
| +54% | +$40.1M | 0.01% | 952 |
|
|
2026
Q1 | $71.5M | Buy |
414,728
+97,109
| +31% | +$18M | 0.01% | 1282 |
|
|
2025
Q4 | $63.4M | Buy |
317,619
+78,407
| +33% | +$14.2M | 0.01% | 1310 |
|
|
2025
Q3 | $37.4M | Sell |
239,212
-139,833
| -37% | -$22.2M | ﹤0.01% | 1667 |
|
|
2025
Q2 | $57.5M | Sell |
379,045
-618,443
| -62% | -$82.5M | 0.01% | 1240 |
|
|
2025
Q1 | $150M | Buy |
997,488
+800,762
| +407% | +$134M | 0.02% | 612 |
|
|
2024
Q4 | $36.3M | Buy |
196,726
+43,674
| +29% | +$8.41M | 0.01% | 1570 |
|
|
2024
Q3 | $30.1M | Sell |
153,052
-65,304
| -30% | -$13.6M | ﹤0.01% | 1680 |
|
|
2024
Q2 | $45.1M | Buy |
218,356
+69,115
| +46% | +$15.7M | 0.01% | 1232 |
|
|
2024
Q1 | $40.4M | Sell |
149,241
-5,153
| -3% | -$1.23M | 0.01% | 1300 |
|
|
2023
Q4 | $36.5M | Sell |
154,394
-9,422
| -6% | -$1.85M | 0.01% | 1406 |
|
|
2023
Q3 | $32.1M | Sell |
163,816
-122,168
| -43% | -$25.1M | 0.01% | 1408 |
|
|
2023
Q2 | $60.1M | Buy |
285,984
+82,445
| +41% | +$16.4M | 0.01% | 972 |
|
|
2023
Q1 | $41.1M | Buy |
203,539
+91,804
| +82% | +$20.8M | 0.01% | 1210 |
|
|
2022
Q4 | $24.3M | Sell |
111,735
-6,639
| -6% | -$1.45M | 0.01% | 1770 |
|
|
2022
Q3 | $23.3M | Sell |
118,374
-961
| -0.8% | -$207K | 0.01% | 1739 |
|
|
2022
Q2 | $25.5M | Sell |
119,335
-32,275
| -21% | -$7.89M | 0.01% | 1694 |
|
|
2022
Q1 | $43.1M | Buy |
151,610
+29,005
| +24% | +$8.94M | 0.01% | 1404 |
|
|
2021
Q4 | $46.2M | Sell |
122,605
-680
| -0.6% | -$264K | 0.01% | 1400 |
|
|
2021
Q3 | $50.9M | Buy |
123,285
+3,826
| +3% | +$1.59M | 0.01% | 1275 |
|
|
2021
Q2 | $44.2M | Sell |
119,459
-75,632
| -39% | -$25.3M | 0.01% | 1370 |
|
|
2021
Q1 | $56.5M | Buy |
195,091
+41,510
| +27% | +$11.5M | 0.01% | 1083 |
|
|
2020
Q4 | $38.4M | Sell |
153,581
-120,969
| -44% | -$28.8M | 0.01% | 1329 |
|
|
2020
Q3 | $62.2M | Sell |
274,550
-5,791
| -2% | -$1.2M | 0.02% | 842 |
|
|
2020
Q2 | $48.9M | Sell |
280,341
-101,654
| -27% | -$16.2M | 0.01% | 973 |
|
|
2020
Q1 | $48.2M | Sell |
381,995
-210,166
| -35% | -$31.5M | 0.02% | 885 |
|
|
2019
Q4 | $90.5M | Sell |
592,161
-65,848
| -10% | -$9.12M | 0.02% | 757 |
|
|
2019
Q3 | $87.1M | Sell |
658,009
-119,498
| -15% | -$16M | 0.03% | 740 |
|
|
2019
Q2 | $110M | Sell |
777,507
-24,138
| -3% | -$3.27M | 0.03% | 608 |
|
|
2019
Q1 | $116M | Buy |
801,645
+46,412
| +6% | +$6.1M | 0.04% | 575 |
|
|
2018
Q4 | $85.5M | Buy |
755,233
+37,046
| +5% | +$4.64M | 0.03% | 698 |
|
|
2018
Q3 | $96.6M | Buy |
718,187
+87,485
| +14% | +$10.8M | 0.02% | 787 |
|
|
2018
Q2 | $70.8M | Sell |
630,702
-388,568
| -38% | -$42M | 0.02% | 973 |
|
|
2018
Q1 | $109M | Buy |
1,019,270
+5,252
| +0.5% | +$566K | 0.03% | 722 |
|
|
2017
Q4 | $111M | Sell |
1,014,018
-7,749
| -0.8% | -$843K | 0.03% | 748 |
|
|
2017
Q3 | $110M | Buy |
1,021,767
+274,843
| +37% | +$28.2M | 0.03% | 757 |
|
|
2017
Q2 | $75.6M | Buy |
746,924
+68,229
| +10% | +$6.28M | 0.02% | 970 |
|
|
2017
Q1 | $61M | Sell |
678,695
-12,484
| -2% | -$1.06M | 0.02% | 1091 |
|
|
2016
Q4 | $52.7M | Sell |
691,179
-21,334
| -3% | -$1.62M | 0.01% | 1233 |
|
|
2016
Q3 | $59.4M | Buy |
712,513
+56,977
| +9% | +$4.78M | 0.02% | 1072 |
|
|
2016
Q2 | $54M | Buy |
655,536
+110,026
| +20% | +$9.06M | 0.02% | 1060 |
|
|
2016
Q1 | $41.4M | Buy |
545,510
+169,376
| +45% | +$12.5M | 0.01% | 1209 |
|
|
2015
Q4 | $30.2M | Buy |
376,134
+231,014
| +159% | +$16.7M | 0.01% | 1462 |
|
|
2015
Q3 | $9.22M | Buy |
145,120
+52,146
| +56% | +$3.74M | ﹤0.01% | 2316 |
|
|
2015
Q2 | $6.54M | Sell |
92,974
-6,330
| -6% | -$468K | ﹤0.01% | 2706 |
|
|
2015
Q1 | $7.87M | Buy |
99,304
+14,474
| +17% | +$1.07M | ﹤0.01% | 2492 |
|
|
2014
Q4 | $5.4M | Sell |
84,830
-74,448
| -47% | -$4.67M | ﹤0.01% | 2927 |
|
|
2014
Q3 | $9.52M | Buy |
159,278
+48,035
| +43% | +$2.75M | ﹤0.01% | 2406 |
|
|
2014
Q2 | $5.95M | Sell |
111,243
-9,175
| -8% | -$503K | ﹤0.01% | 2848 |
|
|
2014
Q1 | $7.27M | Buy |
120,418
+1,757
| +1% | +$102K | ﹤0.01% | 2654 |
|
|
2013
Q4 | $6.29M | Sell |
118,661
-192,202
| -62% | -$9.65M | ﹤0.01% | 2820 |
|
|
2013
Q3 | $14.4M | Buy |
310,863
+125,022
| +67% | +$5.74M | 0.01% | 1896 |
|
|
2013
Q2 | $7.63M | Buy |
+185,841
| New | +$7.96M | ﹤0.01% | 2334 |
|
Other funds holding CRL
AI
Goldman Sachs's CRL Position: Q2 2026 in Review
Goldman Sachs increased its Charles River Laboratories (CRL) stake by 54% in Q2 2026, buying an estimated $40.1M and bringing the position to 639,803 shares worth $145M. The position accounts for 0.01% of the portfolio, ranked #952.
Goldman Sachs first reported a position in CRL in Q2 2013 and has held it in 53 quarters since. The position peaked at $150M in Q1 2025. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Goldman Sachs held 639,803 shares of Charles River Laboratories worth $145M as of Q2 2026.
- Goldman Sachs bought 225,075 Charles River Laboratories shares in Q2 2026, an estimated $40.1M.
- Charles River Laboratories made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #952 holding.
- Goldman Sachs first reported a position in Charles River Laboratories in Q2 2013 and has held it in 53 quarters since.
- Goldman Sachs's Charles River Laboratories position peaked at $150M in Q1 2025.
- 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.